Seattle Genetics shares soar on Genentech pact
Shares of Seattle Genetics shot up 31.5 percent this morning after it announced that it would gain $60 million up front and more than $800 million in potential milestones from Genentech from its newly signed development pact for SGN-40. Genentech is committed to pay $20 million of those milestones payments in the first two years of the agreement as Seattle Genetics is reimbursed for clinical trials. The therapy is an early-stage cancer treatment being studied for multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
- check out the release on the deal with Genentech
ALSO: Seattle Genetics has also signed a joint research agreement with Agensys to develop antibody-drug conjugate therapies for cancer. Release
Related Article:
Genentech inks $300M pact with Swiss biotech. Report
Genentech strikes $919M deal to buy Tanox. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
